MFS Research International B holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
MFS Research International Fund Class B MRIBX
- NAV / 1-Day Return 27.82 / +0.36 %
- Total Assets 17.8B
-
Adj. Expense Ratio
1.740%
- Expense Ratio 1.740%
- Distribution Fee Level Low
- Share Class Type Deferred Load
- Category Foreign Large Blend
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Closed
- TTM Yield 0.53%
- Turnover 27%
USD | NAV as of Jun 13, 2026 | 1-Day Return as of Jun 13, 2026, 12:15 AM GMT+0
Morningstar’s Analysis MRIBX
Will MRIBX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the MRIBX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of MRIBX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 22.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Mizuho Financial Group Inc | 3.05 | 540M | Financial Services |
Schneider Electric SE | 2.87 | 509M | Industrials |
Hitachi Ltd | 2.42 | 428M | Industrials |
TotalEnergies SE | 2.27 | 402M | Energy |
Novartis AG Registered Shares | 2.12 | 376M | Healthcare |
Taiwan Semiconductor Manufacturing Co Ltd | 2.03 | 359M | Technology |
ASML Holding NV | 2.02 | 357M | Technology |
AstraZeneca PLC | 1.86 | 328M | Healthcare |
Linde PLC | 1.81 | 320M | Basic Materials |
Tokyo Electron Ltd | 1.76 | 312M | Technology |
United States